JP2015505843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505843A5 JP2015505843A5 JP2014546255A JP2014546255A JP2015505843A5 JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5 JP 2014546255 A JP2014546255 A JP 2014546255A JP 2014546255 A JP2014546255 A JP 2014546255A JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- biologically active
- pharmaceutical composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576034P | 2011-12-15 | 2011-12-15 | |
| US61/576,034 | 2011-12-15 | ||
| PCT/CA2012/050899 WO2013086636A1 (en) | 2011-12-15 | 2012-12-14 | Soluble igf receptor fc fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505843A JP2015505843A (ja) | 2015-02-26 |
| JP2015505843A5 true JP2015505843A5 (https=) | 2016-02-04 |
Family
ID=48611766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546255A Pending JP2015505843A (ja) | 2011-12-15 | 2012-12-14 | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10538575B2 (https=) |
| EP (1) | EP2791338B1 (https=) |
| JP (1) | JP2015505843A (https=) |
| KR (1) | KR20150031217A (https=) |
| CN (1) | CN104066845A (https=) |
| BR (1) | BR112014014418A2 (https=) |
| CA (1) | CA2858389A1 (https=) |
| HK (1) | HK1202587A1 (https=) |
| WO (1) | WO2013086636A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| KR102654033B1 (ko) * | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
| WO2016193497A1 (en) * | 2015-06-04 | 2016-12-08 | Ospedale San Raffaele Srl | Inhibitor of igfbp3/tmem219 axis and diabetes |
| CN107921094B (zh) * | 2015-06-04 | 2022-03-01 | 圣拉斐尔医院有限公司 | Igfbp3及其用途 |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN106520806B (zh) * | 2016-11-03 | 2018-06-19 | 宜明细胞生物科技有限公司 | 一种重组car基因及其载体、car-t细胞和应用 |
| EP3632929A1 (en) | 2018-10-02 | 2020-04-08 | Ospedale San Raffaele S.r.l. | Antibodies and uses thereof |
| CN113092392B (zh) * | 2021-03-05 | 2022-11-08 | 苏州西山中科药物研究开发有限公司 | 一种检测猴血清中靶向可溶性蛋白的单克隆抗体药物总浓度的通用型方法 |
| CN119708266B (zh) * | 2025-02-26 | 2025-06-06 | 首玺(广州)医疗科技有限责任公司 | 一种胰岛素样生长因子-1连接多肽及其在子宫内膜损伤修复中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6084085A (en) | 1995-11-14 | 2000-07-04 | Thomas Jefferson University | Inducing resistance to tumor growth with soluble IGF-1 receptor |
| ES2305886T3 (es) * | 2003-12-30 | 2008-11-01 | Merck Patent Gmbh | Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo. |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| WO2007021807A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
| GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| JP2010518140A (ja) * | 2007-02-14 | 2010-05-27 | グラクソ グループ リミテッド | Ｉｇｆ−１ｒに対する新規抗体 |
| AU2008223541B2 (en) * | 2007-03-02 | 2012-04-05 | Amgen Inc. | Methods and compositions for treating tumor diseases |
| CA2694055A1 (en) * | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| JP2011526792A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| JP2011529452A (ja) * | 2008-07-29 | 2011-12-08 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ | 抗血管新生薬としての可溶性ｉｇｆ受容体 |
| DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| WO2010136480A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
-
2012
- 2012-12-14 HK HK15103272.6A patent/HK1202587A1/xx unknown
- 2012-12-14 JP JP2014546255A patent/JP2015505843A/ja active Pending
- 2012-12-14 CA CA2858389A patent/CA2858389A1/en not_active Abandoned
- 2012-12-14 US US14/365,250 patent/US10538575B2/en active Active
- 2012-12-14 KR KR20147019486A patent/KR20150031217A/ko not_active Withdrawn
- 2012-12-14 WO PCT/CA2012/050899 patent/WO2013086636A1/en not_active Ceased
- 2012-12-14 BR BR112014014418A patent/BR112014014418A2/pt not_active IP Right Cessation
- 2012-12-14 EP EP12857915.8A patent/EP2791338B1/en active Active
- 2012-12-14 CN CN201280067765.6A patent/CN104066845A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505843A5 (https=) | ||
| Feldman | Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments | |
| JP6857498B2 (ja) | 癌を処置するための併用方法 | |
| Yu et al. | Potential approaches to the treatment of Ewing's sarcoma | |
| Caffo et al. | Innovative therapeutic strategies in the treatment of brain metastases | |
| JP2015529641A5 (https=) | ||
| JP2018521135A5 (https=) | ||
| CN112867503A (zh) | 掩蔽的细胞因子缀合物 | |
| JP2017171685A5 (https=) | ||
| EA200701250A1 (ru) | Иммуноконъюгаты против интегрина, способы и варианты применения | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JP2012067116A5 (https=) | ||
| JP2016502515A5 (https=) | ||
| US20220056450A1 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
| JP2017534259A5 (https=) | ||
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| JP2013511559A5 (https=) | ||
| JP2014523398A5 (https=) | ||
| Zhao et al. | IL10-modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition | |
| JP2023532032A (ja) | 血液脳関門浸透アプタマー及びその利用 | |
| JP2018509423A5 (https=) | ||
| JP2014525412A5 (https=) | ||
| CN106924260B (zh) | 化合物在制备用于治疗脑胶质瘤的药物中的用途 | |
| de Oliveira Silva et al. | New avenues for the treatment of immunotherapy-resistant pancreatic cancer | |
| Lu et al. | Cancer-associated fibroblasts: central players in cancer hallmarks and therapeutic resistance |